Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) will be releasing its earnings data before the market opens on Thursday, November 14th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same quarter in the prior year, the business posted ($0.72) EPS. On average, analysts expect Chemomab Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Chemomab Therapeutics Stock Down 0.3 %
Shares of CMMB stock opened at $1.43 on Thursday. Chemomab Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.55. The stock’s 50-day moving average price is $1.64 and its 200 day moving average price is $1.23. The stock has a market capitalization of $20.53 million, a PE ratio of -1.25 and a beta of 0.53.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Featured Articles
- Five stocks we like better than Chemomab Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- What a Trump Win Looks Like for the Market Now and Into 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What is MarketRankā¢? How to Use it
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.